SCHEMBL508724

SCHEMBL508724

C=C(C)C(=O)Nc1ccc(O)c(-n2nc3ccc(Cl)cc3n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 2/20 0.41
BAZ1A Q9NRL2 1/20 0.41
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CASP3 P42574 2/20 0.37
SENP7 Q9BQF6 2/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29400067 1.00 RXFP1 (0.42) RXFP1MAPTTP53BAZ1ANPC1
SCHEMBL21372495 0.92 MAPT (0.45) RXFP1MAPTTP53NPC1RAB9A
SCHEMBL21586955 0.88 RXFP1 (0.46) RXFP1MAPTTP53NPC1RAB9A
SCHEMBL4453094 0.87 RAB9A (0.52) RXFP1MAPTBAZ1ANPC1RAB9A
SCHEMBL3376787 0.85 RAB9A (0.54) RXFP1MAPTTP53BAZ1ANPC1
SCHEMBL30887146 0.85 RAB9A (0.54) RXFP1MAPTTP53BAZ1ANPC1
SCHEMBL508333 0.84 MAPT (0.46) RXFP1MAPTTP53BAZ1ANPC1
SCHEMBL29400036 0.84 MAPT (0.46) RXFP1MAPTTP53BAZ1ANPC1
SCHEMBL320934 0.82 NPC1 (0.47) MAPTTP53BAZ1ANPC1RAB9A
SCHEMBL28161467 0.82 LMNA (0.37) RXFP1MAPTTP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595368-B2 UV/HEVL-filtering contact lenses ALCON INC. (CH) 2026-04-07 US claimed
US-20250223392-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC (CH) 2025-07-10 US claimed
US-12286501-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof ALCON INC. (CH) 2025-04-29 US claimed
US-20240254269-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC. (CH) 2024-08-01 US claimed
US-11926689-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof ALCON INC. (CH) 2024-03-12 US claimed
WO-2023228055-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-30 WO claimed
US-20230374306-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-23 US claimed
EP-3303415-B1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF ALCON INC (CH) 2022-12-28 EP claimed
US-20220380509-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC. (CH) 2022-12-01 US claimed
US-11453736-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof ALCON INC. (CH) 2022-09-27 US claimed
WO-2014095690-A1 METHOD FOR MAKING IMPROVED UV-ABSORBING OPHTHALMIC LENSES NOVARTIS AG (CH) 2014-06-26 WO claimed
US-20130095235-A1 METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES NOVARTIS AG (CH) 2013-04-18 US claimed
WO-2013055746-A1 METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES BY COATING NOVARTIS AG (CH) 2013-04-18 WO claimed
US-8383744-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2013-02-26 US claimed
EP-2480927-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES Novartis AG (CH) 2012-08-01 EP claimed
EP-2432808-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS Novartis AG (CH) 2012-03-28 EP claimed
WO-2011034801-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES NOVARTIS AG (CH) 2011-03-24 WO claimed
US-20110063567-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES ALCON INC. (CH) 2011-03-17 US claimed
WO-2010133680-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2010-11-25 WO claimed
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS ALCON INC. (CH) 2010-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS VCL, MACF1, CFL1 RXFP1 4091/4885MAPT 2721/4885TP53 3849/4885
US-12595368-B2 UV/HEVL-filtering contact lenses UACA, HSPA4L, RAD54L RXFP1 3756/4885MAPT 453/4885TP53 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.